Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
Inv. presentation
Asset disposition
Appointed CFO
Quarterly results
Director departure
Appointed director
ARCA biopharma, Inc. (ABIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/24/2023 8-K Quarterly results
Docs: "ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, February 24, 2023 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate strategic options for maximizing stockholder value. Potentia..."
08/02/2022 8-K Quarterly results
Docs: "Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..."
05/02/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------"
08/04/2021 8-K Quarterly results
Docs: "Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID‑19 expanded to South America • Topline data anticipated in the fourth quarter of 2021 Westminster, CO, August 4, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We continue to be encouraged with the opportunities we see in our development pipeline compounds, rNAPc2 and Gencaro. With the ASPEN-COVID-19 Phase 2b trial of rNAPc2 expanding to South America, we look forward to completing the trial and we anticipate sharing the res..."
05/11/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
Docs: "Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID‑19 anticipated in the third quarter of 2021 • New patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions greater than 40% Westminster, CO, March 18, 2021 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are currently actively enrolling patients in a Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19 who..."
11/02/2020 8-K Quarterly results
Docs: "Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID‑19 anticipated in fourth quarter • Topline data from trial anticipated Q2 2021 Westminster, CO, November 2, 2020 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the third quarter of 2020 and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “With the resurgence of SARS-CoV-2 across the country and around the globe, the need for effective therapies to treat patients hospitalized with COVID-19 remains an urgent priority. AB201’s combination of anticoagulant, anti-inflammatory and an..."
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/18/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020 • Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies Westminster, CO, November 6, 2019 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2019 and provided a corporate update. “There are currently no FDA approved drug therapies indicated for treating patients with atrial fibrillation and heart failure with left ventricular ejection fraction values greater than 40%,” commented Dr. Michael Bristow, ARCA’s President and Chief Executive Officer. “Appro...",
"Investor Presentation titled “ARCA biopharma Pharmacogenetic Precision Medicine for Cardiovascular Diseases”"
08/01/2019 8-K Quarterly results
Docs: "FDA SPA Agreement for Phase 3 atrial fibrillation trial amended to expand patient population to include heart failure patients with preserved ejection fraction - PRECISION-AF clinical trial initiation anticipated in the first quarter of 2020 Westminster, CO, August 1, 2019 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2019 and provided a corporate update. “We continue to make important progress on our lead development program Gencaro building on our GENETIC-AF Phase 2B clinical trial results, which were published in the Journal of the American College of Cardiology: Heart Failure,” commented Dr. Michael Brist..."
05/08/2019 8-K Quarterly results
Docs: "ARCA Biopharma announces first quarter 2019 financial results AND Provides CorporatE update",
"Investor Presentation titled “ARCA biopharma Pharmacogenetic Precision Medicine for Cardiovascular Diseases”"
02/27/2019 8-K Quarterly results
03/22/2018 8-K Quarterly results
Docs: "ARCA Biopharma announces fiscal year 2017 financial results AND Provides Corporate update --------------------------------------------------------------------------------------------------"
11/09/2017 8-K Quarterly results
Docs: "ARCA Biopharma announces THIRD quarter 2017 financial results and provides business update --------------------------------------------------------------------------------------------------"
08/03/2017 8-K Quarterly results
Docs: "ARCA Biopharma announces SECOND quarter 2017 financial results and provides business update --------------------------------------------------------------------------------------------------"
05/15/2017 8-K Quarterly results
Docs: "ARCA Biopharma announces first quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- Outcome of GENETIC-AF Phase 2B Interim Efficacy Analysis"
03/21/2017 8-K Form 8-K - Current report
11/14/2016 8-K Quarterly results
Docs: "ARCA Biopharma announces THIRd quarter 2016 financial results and provides business update -------------------------------------------------------------------------------"
08/09/2016 8-K Quarterly results
Docs: "ARCA Biopharma announces second quarter 2016 financial results and provides business update ------------------------------------------------------------------------------- Outcome of GENETIC-AF Clinical Trial Interim Efficacy Analysis Anticipated"
03/17/2016 8-K Quarterly results
Docs: "ARCA Biopharma announces fiscal year 2015 financial results and provides business update --------------------------------------------------------------------------------------------------"
10/30/2008 8-K Quarterly results
Docs: "NUVELO REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS"
07/23/2008 8-K Quarterly results
Docs: "NUVELO REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS"
05/08/2008 8-K Quarterly results
Docs: "NUVELO REPORTS FIRST QUARTER 2008 FINANCIAL RESULTS AND UPDATED OUTLOOK FOR 2008"
11/01/2007 8-K Quarterly results
Docs: "NUVELO REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS"
08/01/2007 8-K Quarterly results
Docs: "PRESS RELEASE TITLED "NUVELO REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS"",
"NUVELO REDUCES EXPENSES AND REALIGNS ORGANIZATION TO FOCUS ON PROGRAMS EXPECTED TO YIELD NEAREST-TERM PROOF-OF-CONCEPT DATA"
05/09/2007 8-K Quarterly results
Docs: "NUVELO REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS"
11/02/2006 8-K Quarterly results
Docs: "NUVELO REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS AND ACCOMPLISHMENTS"
08/03/2006 8-K Quarterly results
Docs: "NUVELO REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS AND ACCOMPLISHMENTS"
05/05/2006 8-K Quarterly results
Docs: "NUVELO REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS AND ACCOMPLISHMENTS"
11/01/2005 8-K Quarterly results
Docs: "NUVELO REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS AND ACCOMPLISHMENTS"
08/04/2005 8-K Quarterly results
Docs: "PRESS RELEASE TITLED "NUVELO REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS"",
"Data sheet issued by Nuvelo, Inc."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy